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Abstract
Introduction: Persistent infection with GBV-C (GB Virus C), a non-pathogenic virus related to hepatitis C virus (HCV),
prolongs survival in HIV infection. Two GBV-C proteins, NS5A and E2, have been shown previously to inhibit HIV replication
in vitro. We investigated whether the GBV-C NS3 serine protease affects HIV replication.
Results: GBV-C NS3 protease expressed in a human CD4+ T lymphocyte cell line significantly inhibited HIV replication.
Addition of NS4A or NS4A/4B coding sequence to GBV-C NS3 increased the effect on HIV replication. Inhibition of HIV
replication was dose-dependent and was not mediated by increased cell toxicity. Mutation of the NS3 catalytic serine to
alanine resulted in loss of both HIV inhibition and protease activity. GBV-C NS3 expression did not measurably decrease CD4
or CXCR4 expression.
Conclusion: GBV-C NS3 serine protease significantly inhibited HIV replication without decreasing HIV receptor expression.
The requirement for an intact catalytic serine at the active site indicates that inhibition was mediated by proteolytic
cleavage of an unidentified target(s).
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Introduction
Persistent infection with GB virus C (GBV-C) delays progression
of HIV disease and significantly improves survival in HIV
infection [1–5]. HIV/GBV-C coinfected people have delayed
CD4+ T cell depletion, lower HIV viral loads, delayed progression
to AIDS, and better response to HIV therapy than people infected
with HIV alone [1–3,5–13]. Untreated HIV-infected men with
persistent GBV-C viremia, defined as GBV-C RNA detected in
serum 5 or more years apart, have a 75% 10 year survival rate
compared with 39% for untreated HIV-infected men without
GBV-C viremia (p=0.006) [2]. HIV-infected people with GBV-C
viremia detected 2 or more years after HIV seroconversion have a
59% reduction in the risk of death compared with HIV-infected
people who do not have GBV-C viremia [3]. GBV-C/HIV
coinfected people treated with highly active anti-retroviral therapy
(HAART) are significantly more likely to have a complete virologic
response after initiation of therapy (46% vs. 28%, p=0.036), and
have a significantly larger median CD4+ T cell increase (240 cells/
mL vs. 150 cells/mL, p=0.05) [12]. GBV-C viremia is found in
approximately 40% of HIV-infected people [1,2], thus the effect of
GBV-C on HIV disease potentially has a significant impact on
outcomes in HIV-infected populations. GBV-C infection may also
reduce the risk of HIV acquisition in some populations; maternal-
to-child transmission of GBV-C reduces the risk of infant infection
with HIV by 7-fold from 12% to 2% (p,0.001) [14].
GBV-C is a member of the family Flaviviridae and is the most
closely related human virus to hepatitis C virus (HCV) [15]. Both
GBV-C and HCV are single-strand positive sense RNA viruses
whose proteins are translated as a single polyprotein (Fig. 1A); viral
proteins are cleaved to their mature sizes by cellular and viral
proteases [15,16]. The largest protein in both the GBV-C and
HCV open reading frames is non-structural protein 3 (NS3),
which encodes a serine protease in the amino terminal end
(Fig. 1B) and a helicase/ATPase in the carboxy terminal end
[15,17–21]. The protease catalytic residues histidine, aspartate,
and serine are conserved between GBV-C and HCV (Fig. 1B)
[17], however homology between the known cleavage substrates of
GBV-C and HCV NS3 protease is limited (Fig. 1C). The NS3
protease of both GBV-C and HCV must be co-expressed with
NS4A for efficient enzymatic activity [17,20,22,23]. GBV-C NS3/
4A mediates cleavage of NS3/NS4A, NS4B/NS5A, and NS5A/
NS5B [17]. Cleavage is not detectable when the protease catalytic
serine (residue 137) is mutated to alanine [17], similar to the
proteases of HCV and other Flaviviruses [24,25]. The residues of
GBV-C NS4A which must be co-expressed with NS3 for efficient
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George  e al     t         cleavage have been identified through deletion mapping [17]. The
carboxy termini of NS3 and NS4A have not been experimentally
determined, but the amino termini of NS3 and NS5A have been
determined [17], thus the residues in the NS3/4A/4B polyprotein
are known. The HCV NS3 protease cleaves a number of cellular
proteins as well as the viral nonstructural proteins, including
interferon mitochondrial antiviral signaling protein (MAVS) [26–
28] and TRIF [29], altering intracellular signal transduction and
initiation of a type I interferon response. The GBV-C NS3
protease has not been reported to cleave any non-GBV-C
proteins.
The inhibitory mechanism of GBV-C infection on HIV
replication has been partially characterized. In studies using
whole virus from human serum or transfected viral RNA,
coinfection of human peripheral blood mononuclear cells
(PBMCs) and CD4+ T cells with GBV-C significantly inhibits
HIV replication in vitro [1,30,31]. GBV-C infection of PBMCs and
CD4+ T cells increases secretion of CCR5 ligand chemokines and
decreases CCR5 expression by 50% compared with mock-infected
PBMCs [30,31]. Two GBV-C proteins, NS5A [32–35] and the
envelope glycoprotein E2 [36–40], inhibit HIV replication in
CD4+ Jurkat cells by either decreasing HIV receptor expression
(NS5A) or blocking HIV attachment and entry (E2). NS5A
expressed in CD4+ Jurkat T cells inhibits HIV replication by
decreasing expression of CD4 [35] and CXCR4 [32–34]. This
effect is mediated in part by enhanced secretion of the CXCR4
ligand chemokine SDF-1 [33,34]. GBV-C peptides derived from
the E2 protein bind to HIV gp41 fusion peptide, blocking HIV
binding [37,38,40]. Anti-GBV-C E2 antibodies neutralize infec-
tious HIV particles and HIV gag particles, however they do not
inhibit entry of HIV pseudotyped VSV particles [39]. Anti-E2
antibodies interfere with HIV attachment to cell membranes but
do not block HIV entry to cells [39]. The authors propose that
anti-E2 antibodies neutralize HIV by interacting with a cellular
antigen on HIV particles [39]. In addition to these characterized
HIV inhibitory mechanisms, GBV-C infection in vivo decreases T
cell activation independently of HIV viral load [41], though the
mechanism is unknown.
Here, we explored whether expression of GBV-C NS3 in a
CD4+ T lymphocyte cell line affects HIV replication. Since the
homologous HCV protease cleaves multiple viral and cellular
proteins (Fig. 1C) [17,42], we hypothesized that GBV-C protease
may perturb the cellular environment sufficiently to affect HIV
replication.
Results
We first determined whether GBV-C NS3 is a functional
protease when expressed in CD4+ Jurkat cells. Jurkats were chosen
as host cells to approximate the natural CD4+ T lymphocyte host
cell of both GBV-C [43] and HIV. The coding sequences for NS3,
NS3/4A, and NS3/4A/4B were separately amplified from a full-
length GBV-C genome (GenBank AY196904) [44] and inserted
into pCDNA3.1/Zeo+ (Fig. 1A). The carboxy termini of NS3 and
NS4A had to be approximated as they have not been
experimentally determined [17]. To measure proteolytic cleavage
of the NS3/4A/4B polyprotein, we inserted HA-tags on the
amino- and carboxy-termini of NS3/4A/4B (Fig. 2A). To
determine if detectable proteolytic cleavage would be lost with
mutation of the catalytic serine, as described previously [17], we
mutated serine 137 to alanine, creating the carboxy terminally
HA-tagged construct S137A (Fig. 2A).
As shown in Figure 2B, a 73kDa band corresponding to the
predicted size of HA-NS3 was seen in lysates of cells transfected
with HA-NS3/4A/4B, and a 30kDa band corresponding to the
predicted size of NS4B-HA was seen in lysates of cells transfected
with NS3/4A/4B-HA. A 102kDa band corresponding to the
predicted size of full-length NS3/4A/4B was seen in lysates of cells
transfected with S137A-HA. Lysates of cells transfected with
S137A-HA did not show a either a 73kDa band corresponding to
NS3 or a 30kDa band corresponding to NS4B, indicating
proteolytic activity was lost with mutation of the catalytic serine.
Figure 1. Schematic of the GBV-C genome and protein
expression constructs. (A) The GBV-C genome, including the 59
and 39 non-translated regions (NTR), is shown. The structural genes
include the envelope proteins E1 and E2, and the non-structural genes
include NS2, NS3, NS4A, NS4B, NS5A, and NS5B. The regions coding for
NS3, NS3/4A, and NS3/4A/4B that were cloned are shown. The relative
position of the NS3 serine protease catalytic serine residue (S137) is
shown. (B) Comparison of the HCV and GBV-C serine protease catalytic
triad. Partial protease sequences of HCV1b (CON1 sequence), HCV1a
(H77 sequence), HCV2a (JFH-1 sequence), are compared with the GBV-C
AY196904 sequence. The catalytic triad consists of histidine 56, aspartic
acid 79, and serine 137 (blue letters, underlined and in bold). Histidine
56 and serine 137 are expressed in similar peptide contexts in both
HCV and GBV-C (blue letters). The GBV-C residues are numbered from
the experimentally determined amino terminus of GBV-C NS3.
(C) Comparison of the known cleavage recognition sequences of
the HCV and GBV-C NS3 serine proteases. *Adapted from [42].
**Adapted from [17,18].
doi:10.1371/journal.pone.0030653.g001
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HA-NS3/4A/4B or NS3/4A/4B-HA, indicating proteolytic
cleavage was sufficiently rapid to prevent detectable accumulation
of the precursor polyprotein. To evaluate the longevity of protein
expression in this system, we transfected cells with NS3/4A/4B-
HA and measured protein expression for six days by western
analysis (Fig. 2C). Equal numbers of viable cells were harvested on
days 1, 3, and 6 post transfection and lysed in the same volume of
buffer. The same volume of cell lysate was separated on SDS-
PAGE gels and GBV-C protein expression was measured in
parallel (Fig. 2C). GBV-C protein expression remained essentially
unchanged between days 1 and 3 and was still detectable though
diminished on day 6.
To determine whether expression of GBV-C NS3/4A/4B
caused significant cellular toxicity, we compared viability and
proliferation of Jurkat cells transfected with plasmids expressing
GBV-C NS3/4A/4B, GBV-C NS5A (amplified from GBV-C
clone AY196904 [44]), chloramphenicol acetyl transferase (CAT),
luciferase, or empty vector for up to 10 days. All proteins were
expressed from pCDNA3.1/Zeo+. CAT and luciferase expression
plasmids were used as irrelevant protein controls. Expression of
both CAT and luciferase in transfected cells was confirmed by
CAT ELISAs and luciferase assays (data not shown). As shown in
Figures 3A and B, there was no difference in viability or
proliferation of cells transfected with GBV-C or control protein
expression plasmids for up to 10 days after transfection.
To investigate whether GBV-C NS3 expression affected HIV
replication, we transfected Jurkat cells with plasmids expressing
either NS3, NS3/4A, NS3/4A/4B, CAT, glutathione-s-transfer-
ase (GST), or empty vector plus the HIV pNL4-3 genomic
expression plasmid [45]. NS3 expressed without NS4A would be
expected to have less efficient protease activity than NS3 expressed
with NS4A based on homology with HCV [20,22,23]. As the
carboxy terminus of NS4A has not been experimentally
determined, we transfected cells with NS3/4A/4B to ensure we
were expressing the full-length NS4A protein. HIV pNL4-3
Figure 2. GBV-C NS3/4A/4B expression and protease activity in
Jurkat cells. (A) Relative primary structures of the GBV-C proteins
employed are shown. HA indicates the location of the HA epitope tag.
The location of serine 137 is indicated along with the relative sizes of
NS3 and NS4B. (B) CD4+ Jurkat cells were transfected with equal
amounts of HA-NS3/4A/4B, NS3/4A/4B-HA, or S137A-HA expression
plasmids and cell lysates were collected one day post transfection. Cell
lysates were analyzed by western blot developed with an anti-HA
monoclonal antibody. Molecular weight markers are shown at right,
and the mobility of NS3 (73kDa), NS4B (30kDa), or the complete
polypeptide S137A (102kDa) is shown at left. (C) Jurkat cells were
transfected with NS3/4A/4B-HA and equal numbers of viable cells
determined by trypan blue staining were lysed on days 1, 4, and 6 post
transfection. Protein from lysates was analyzed by western blots
developed with an anti-HA monoclonal antibody. Expression of GBV-C
NS3/4A/4B-HA on days 1, 4, and 6 post transfection is shown compared
with cell lysates from cells transfected with NS3/4A/4B and a highly
concentrated NS3/4A/4B-HA cell lysate. Molecular weight markers are
indicated at the left, and the mobility of NS4B-HA (30kDa) is indicated at
the right. A western blot of actin from the same cell lysates run in
parallel is shown below as a loading control.
doi:10.1371/journal.pone.0030653.g002
Figure 3. Transfection of Jurkat cells with GBV-C NS3/4A/4B or
NS5A expression plasmids does not cause cellular toxicity.
Jurkat cells were transfected with equal amounts of NS3/4A/4B (red
line), NS5A (solid black line), or control protein (CAT, luciferase)
expression plasmids in pCDNA3.1/Zeo+ or empty vector (dotted black
lines). Cellular viability (A) and proliferation (B) were measured for 10
days. Standard errors for each measurement on each day are shown.
doi:10.1371/journal.pone.0030653.g003
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ensure efficient HIV replication during the time the transfected
GBV-C or control proteins were maximally expressed (Fig. 2C).
As shown in Figure 4, expression of both NS3/4A and NS3/
4A/4B significantly inhibited HIV replication through day 9,
while NS3 expressed alone was less inhibitory. NS3/4A/4B
significantly inhibited HIV replication compared with CAT
(p,0.001), empty vector (p,0.001), and GST (p,0.01) on day
9. NS3/4A significantly inhibited HIV compared with CAT
(p,0.01) and vector (p,0.001) on day 9. NS3/4A inhibited HIV
compared with GST on day 9, but the difference was not
statistically significant. While a difference in HIV replication
between cells transfected with NS3 compared with CAT, GST, or
empty vector was apparent, the difference was not statistically
significant. Expression of NS3/4A/4B inhibited HIV replication
starting on day 3 post-transfection and continued through day 9.
Expression of NS3/4A or NS3 inhibited HIV replication by day 6
post-transfection. While there was a trend to stronger inhibition by
expression of NS3/4A/4B compared with NS3/4A, the difference
was not statistically significant.
Therefore, expression of GBV-C NS3, NS3/4A, and NS3/4A/
4B inhibited HIV replication in Jurkat cells compared with cells
transfected with two irrelevant control proteins. Addition of NS4A
coding sequence to NS3 increased the inhibitory effect on HIV
replication, potentially pointing to a role for NS3 enzymatic
activity in inhibition of HIV [17,20,22,23]. Since expression of
NS3/4A/4B was somewhat more inhibitory for HIV replication
than expression of NS3/4A, and both plasmids had equal effects
on cellular viability and proliferation (data not shown), either: 1)
NS4B expression had a separate inhibitory effect on HIV
replication, 2) NS4B enhanced the stability, localization, or
enzymatic activity of NS3/4A [46], or 3) our NS3/4A construct
did not contain the full-length NS4A sequence, and thus its
enzymatic activity and inhibitory effect was reduced relative to
NS3/4A/4B.
To confirm that expression of NS3/4A alone could inhibit HIV
replication in Jurkat cells, we transfected cells with the expression
plasmid for NS3/4A or empty vector plus HIV pNL4-3 plasmid or
HIV pNL4-3 plasmid alone. GBV-C NS3/4A expression
significantly inhibited accumulation of p24 in supernatants
(p,0.001 on day 7), while equivalent amounts of empty vector
did not (Fig. 5A). To determine if NS3/4A’s inhibitory effect on
HIV was dose-dependent, we transfected Jurkat cells with 6 or
9 mg NS3/4A expression plasmid or equal amounts of CAT
expression plasmid plus HIV pNL4-3 plasmid. As shown in
Figure 5B, 6 mg of NS3/4A expression plasmid significantly
inhibited HIV replication compared with equivalent amounts of
CAT expression plasmid on day 6 (p,0.001). 9 mg of NS3/4A
expression plasmid significantly inhibited HIV replication com-
pared with equivalent amounts of CAT expression plasmid on
days 3 (p,0.01) and 6 (p,0.001). Thus, increasing the dose of
NS3/4A expression plasmid increased the inhibitory effect on
HIV replication.
Since addition of NS4A or NS4A/4B coding sequences to NS3
substantially increased its inhibitory effect on HIV replication and
thus implicated NS3 enzymatic activity in the mechanism of
inhibition (Fig. 4), we investigated whether mutation of the NS3
protease catalytic serine 137 to alanine would result in loss of the
HIV inhibitory effect. Since our western blot data demonstrated
that mutation of serine 137 to alanine (S137A) resulted in loss of
detectable protease cleavage products (Fig. 2B), we compared
inhibition of HIV replication in cells transfected with either NS3/
4A, NS3/4A/4B, S137A, NS5A, CAT, or luciferase expression
plasmids or vector plus HIV pNL4-3 (Fig. 6). NS5A expression
Figure 4. Expression of GBV-C NS3, NS3/4A, or NS3/4A/4B in
Jurkat cells inhibits HIV replication for up to 9 days. Jurkat cells
were transfected with equal amounts of plasmids expressing NS3 (solid
black line), NS3/4A (blue line), NS3/4A/4B (red line), GST, CAT, or empty
vector (dotted black lines) plus HIV pNL4-3 plasmid. Mean and standard
error p24 values of supernatants collected on days 1, 3, 6, and 9 are
shown.
doi:10.1371/journal.pone.0030653.g004
Figure 5. GBV-C NS3/4A inhibition of HIV replication in Jurkat
cells is dose-dependent. (A) Jurkat cells were transfected with either
3 mg HIV pNL4-3 (HIV), 3 mg of HIV pNL4-3+3 mg pCDNA3.1/Zeo+
(HIV+vector), or 3 mg HIV pNL4-3+3 mg NS3/4A in pCDNA3.1/Zeo+
(HIV+NS3/4A) (blue line). Mean and standard errors of p24 values in
supernatants collected on days 1, 3, and 7 are shown. (B) Jurkat cells
were transfected with HIV pNL4-3 and either 6 or 9 mg of NS3/4A
expression plasmid (blue lines) or equivalent amounts of CAT
expression plasmid; mean and standard errors of p24 values in
supernatants collected on days 1, 3, and 6 are shown.
doi:10.1371/journal.pone.0030653.g005
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There was no significant difference in p24 values between
supernatants of cells transfected with S137A, CAT, or luciferase
expression plasmids or empty vector (Fig. 6). There was also no
significant difference in p24 values between supernatants of cells
transfected with NS3/4A, NS3/4A/4B or NS5A. There was a
trend toward stronger inhibition by NS3/4A/4B and NS5A
compared with NS3/4A but the difference was not statistically
significant. NS3/4A, NS3/4A/4B, and NS5A significantly
inhibited HIV replication compared with S137A, CAT, and
luciferase expression plasmids and empty vector on day 7
(p,0.001). NS3/4A/4B and NS5A significantly inhibited HIV
replication compared with S137A, CAT, and luciferase expression
plasmids and empty vector on day 5 (CAT and S137A, p,0.01;
luciferase and vector, p,0.05), while NS3/4A significantly
inhibited HIV replication compared with S137A and CAT on
day 5 (S137A, p,0.01; CAT, p,0.05). Therefore, mutating the
protease catalytic serine to alanine resulted in loss of both
measurable proteolytic activity (Fig. 2B) and inhibition of HIV
replication (Fig. 6).
As GBV-C NS5A expression decreases CD4 and CXCR4
expression in Jurkat cells in vitro [32–35], we investigated whether
GBV-C NS3/4A/4B decreased HIV receptor expression in
transfected Jurkat cells. The NS3/4A/4B construct was chosen
as it expresses NS3, NS4A, and NS4B and inhibited HIV
replication as much as NS5A expression in this system (Fig. 6).
Since no antibodies are available which reliably detect GBV-C
NS3, NS4A, or NS4B expression, and we wished to avoid the use
of an HA tag and express only the native proteins, Jurkat cells were
transfected with 1 mg green fluorescent protein (GFP) in
pCDNA3.1/Zeo+ as a marker of protein expression after
transfection plus either 6 mg NS3/4A/4B or CAT expression
plasmids and a scrambled human CD4 siRNA control [47,48]. As
a positive control to demonstrate suppression of a cell surface
marker on these cells, we co-transfected cells with anti-human
CD4 siRNA plus 1 mg GFP and 6 mg CAT expression plasmid
[47,48].
We compared CD4 and CXCR4 expression on Jurkat cells
transfected with NS3/4A/4B or CAT expression plasmids on days
3, 4, and 5 after transfection. These days were chosen based on
preliminary experiments identifying the time required to demon-
strate CD4 knockdown in CD4 siRNA transfected cells. Equal
numbers of viable cells were collected on each day and gated for
GFP expression by comparison with cells transfected with CAT
expression plasmid and scrambled CD4 siRNA but no GFP.
GFP+ cells were analyzed for CD4 and CXCR4 expression. The
percent of cells expressing GFP ranged from 39–65% on day 3,
36–57% on day 4, and 34–51% on day 5 (data not shown). There
was no difference in the percentage of cells expressing GFP in cells
transfected with NS3/4A/4B compared with CAT expression
plasmids. As shown in Figures 7A and C, there was no difference
in CD4 expression in cells transfected with NS3/4A/4B compared
with CAT expression plasmids on days 3 and 4. There was a trend
to a slight decrease in CD4 expression in cells transfected with
NS3/4A/4B compared with CAT expression plasmids on day 5,
but peak expression was not significantly shifted (Fig. 7E). There
was a significant decrease in the mean fluorescent intensity (MFI)
of CD4 expression in cells transfected with CD4 siRNA compared
with cells transfected with scrambled CD4 siRNA and CAT or
Figure 6. Mutating the protease catalytic serine of GBV-C NS3/
4A/4B to alanine results in loss of HIV inhibition. Jurkat cells were
transfected with HIV pNL4-3 and equal amounts of NS3/4A (blue line),
NS3/4A/4B (red line), NS5A (solid black line), S137A (dotted red line),
CAT, or luciferase expression plasmids or empty vector (dotted black
lines). Supernatants were collected and p24 measured on days 1, 3, 5,
and 7. Mean and standard error of p24 values are shown.
doi:10.1371/journal.pone.0030653.g006
Figure 7. GBV-C NS3/4A/4B expression does not decrease CD4
or CXCR4 expression. Jurkat cells were transfected with 1 mg GFP in
pCDNA3.1/Zeo+ and either 6 mg NS3/4A/4B expression plasmid (red
line) or CAT expression plasmid (blue line) and scrambled anti-CD4
siRNA. Equal numbers of viable cells were labeled with anti-CD4 PE-
Cy7 and anti-CXCR4-APC and analyzed by FACS on days 3 (A and B), 4
(C and D), and 5 (E and F) post transfection. Cells were gated for
GFP expression and then analyzed for CD4 and CXCR4 expression. As a
control to demonstrate reduction in receptor expression, cells were
transfected with 1 mg GFP in pCDNA3.1/Zeo+ and 6 mg CAT expression
plasmid plus anti-CD4 siRNA (A,C,E: gray shaded area, B,D,F: black
line).
doi:10.1371/journal.pone.0030653.g007
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(Figs. 7A, C, E). There was no decrease in CXCR4 expression in
cells transfected with NS3/4A/4B compared with CAT expression
plasmids on days 4 and 5 (Figs. 7D and F). There was a slight
decrease in CXCR4 expression in cells transfected with NS3/4A/
4B compared with CAT expression plasmids on day 3 (Fig. 7B).
There was no decrease in CXCR4 expression in cells transfected
with CD4 siRNA compared with cells transfected with scrambled
CD4 siRNA and NS3/4A/4B or CAT expression plasmids, as
expected (Figs. 7B, D, F). Therefore, we were unable to find
evidence of significant, sustained decreased expression of either
CD4 or CXCR4 in cells transfected with NS3/4A/4B compared
with CAT expression plasmids on days 3, 4, or 5 after transfection.
Since inhibition of HIV replication is seen by 3 days after
transfection of GBV-C expression plasmids (Figs. 4, 5A and B, and
Fig. 6) and is maintained for up to 9 days (Fig. 4), the NS3 protease
inhibits HIV replication by a mechanism other than decreasing
HIV receptor expression.
Discussion
We have shown that transient expression of GBV-C NS3
protease in the human Jurkat CD4+ T cell line significantly
inhibited HIV replication, and that inhibition required an intact
protease catalytic serine (Fig. 6). Mutation of the catalytic serine
137 to alanine resulted in loss of both detectable protease cleavage
products (Fig. 2B) and loss of inhibition of HIV replication (Fig. 6).
While NS3 expressed alone was inhibitory (Fig. 4), addition of
NS4A or NS4A/NS4B coding sequences substantially increased
the inhibitory effect (Fig. 4). These data, combined with the
evidence that an intact catalytic serine was required for inhibition,
provide evidence that inhibition of HIV replication by the GBV-C
NS3 protease was mediated by proteolytic cleavage. What the
cleavage target(s) of the protease are remains unknown. Potential
targets include cleavage of HIV proteins or cleavage of cellular
proteins which HIV requires for efficient replication.
Addition of NS4B coding sequences to NS3/4A consistently
increased the inhibitory effect on HIV replication, though the
difference was not significant (Figs. 4 and 6). Therefore, NS4B
expression may have a modest additional inhibitory effect on HIV
replication independent of NS3/4A. In HCV, NS4B mediates
formation of the membranous web, a region of modified cellular
membranes upon which viral replication occurs [49,50]. Whether
GBV-C NS4B has similar functions is unknown, but given the
homology between GBV-C and HCV, it is plausible that GBV-C
NS4B may disrupt intracellular membranes similar to HCV
NS4B, and this could interfere with efficient HIV replication if
both viruses infect the same CD4+ T cell. It is unknown whether
GBV-C and HIV coinfect the same cells in vivo or in vitro. Whether
GBV-C NS4B has HIV inhibitory effects will need to be defined in
future work.
GBV-C NS3/4A/4B expression did not significantly decrease
CD4 or CXCR4 expression on Jurkat cells on days 3, 4, or 5 post-
transfection (Fig. 7). As inhibition of HIV replication was seen
beginning day 3 and lasting through day 9 post transfection, the
GBV-C protease likely inhibited HIV replication by a mechanism
which does not require decreased HIV receptor expression. This
would be a novel mechanism for GBV-C-mediated inhibition of
HIV.
We found transfected Jurkats were poorly permissive for HIV
infection up to 48 hours after transfection using high-titer
supernatants harvested from pNL4-3 transfected cells which were
infectable into jurkats which had not been transfected (data not
shown). This was seen regardless of the plasmid transfected (GBV-
C or control expression plasmid), so was likely due to nonspecific
cellular effects of the electroporation. This argues that most of the
p24 antigen in our culture supernatants at least through day 3 was
probably translated from mRNA transcribed from the HIV DNA
derived from the pNL4-3 plasmid, and not from a complete viral
infection cycle. Since p24 levels were reduced in supernatants of
cells transfected with GBV-C expression plasmids as early as day 3
post transfection (Fig. 4, Figs. 5A and B, Fig. 6), we hypothesize
that GBV-C serine protease expression may inhibit HIV at a step
after HIV DNA integration, such as mRNA transcription,
processing, translation, or virion assembly. This is in contrast to
GBV-C NS5A and E2 proteins, both of which block HIV
replication at the attachment/entry/fusion steps [32–40].
In summary, we have identified a novel HIV-inhibitory GBV-C
protein, the NS3 protease, which requires an intact catalytic serine
to inhibit HIV replication. In this in vitro system, inhibition of HIV
replication by GBV-C protease was similar in strength to
inhibition by the previously-described GBV-C NS5A protein
[32–35]. Expression of NS3 protease did not decrease HIV
receptor expression. The mechanism by which GBV-C NS3
protease inhibits HIV replication, and the possible role of NS4B in
inhibition of HIV replication, will need to be defined in future
work.
Materials and Methods
Synthesis of GBV-C expression vectors
The coding regions of GBV-C NS3, NS3/4A, NS3/4A/4B,
and NS5A were amplified from the full-length GBV-C AY196904
sequence [44] and inserted into pCDNA3.1/Zeo+ expression
vector (Invitrogen). The coding sequence for NS3 was nt 2682–
4556, NS3/4A was nt 2682–4727, NS3/4A/4B was nt 2682–
5600, and NS5A was nt 5601–6938 (numbered from the
methionine codon at the beginning of E1). The carboxy termini
of NS3 and NS4A have not been experimentally defined, so the
GBV-C NS4A sequence identified as the required cofactor for
activity of the GBV-C NS3 protease was used as the approximate
carboxy terminus of NS3/4A [17]. To avoid including any NS4A
residues in the NS3 construct, the carboxy terminus of NS3 was
placed ten amino acids upstream of the start of the NS4A cofactor
sequence. The NS5A sequence had the same amino and carboxy
termini as the sequence studied by Stapleton et al [32–35],
however it was amplified from a different source GBV-C sequence
(AY196904) [44]. The S137A construct was created from the
NS3/4A/4B sequence by mutating the thymidine residue at
position 3090 to guanine. HA tags were inserted on the amino and
carboxy termini of NS3/4A/4B and the carboxy terminus of
S137A (Fig. 2A) using PCR. Sequences were amplified using
Roche HiFi DNA polymerase and inserts were completely
sequenced.
Control expression plasmids
Chloramphenicol acetyl transferase (CAT) [9], glutathione-s-
transferase (GST), and luciferase [51], all under the control of the
CMV promoter in pCDNA3.1/Zeo+ vector, were used as
irrelevant protein expression controls. Plasmid DNAs for trans-
fection were prepared with endotoxin-free maxipreps (Qiagen).
HIV pNL4-3 plasmid was obtained from the NIH AIDS Reagent
program [45].
Cells
CD4+ CXCR4+ Jurkat cells [52] were maintained in RPMI
supplemented with 10% fetal calf serum and 1% penicillin/
streptomycin/L-glutamine.
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5610
6 Jurkat cells were transfected in triplicate with 6 mg GBV-
C expression or control plasmids using an Amaxa II nucleofection
device, according to the manufacturer’s instructions. Transfected
cells from the triplicate transfections were combined and harvested
on day 1 (Fig. 2B), or duplicate transfections were combined and
lysed on days 1, 3, and 6 (Fig. 2C). Lysis was performed in RIPA
buffer supplemented with protease inhibitor (Sigma), and protein
content measured using BCA assay (Pierce). Cell lysates were
loaded onto 4–20% SDS-PAGE gels, transferred to PVDF
membranes, and western blots were developed with anti-HA high
affinity monoclonal antibody (Roche 3F-10).
Viability and proliferation assays
5610
6 Jurkat cells were transfected with 6 mg GBV-C
expression or control plasmids in triplicate. Viability was measured
by trypan blue staining and proliferation was measured using
BrdU incorporation assays (Roche). For trypan blue staining,
aliquots of cells were mixed with equal amounts of trypan blue and
the number of viable cells was determined on a Cedex cell counter
(Roche). For BrdU assays, cells were counted on day 1 post-
transfection and each transfection was plated in duplicate in ten 96
well plates (20,000 cells/well) to provide one plate per timepoint
per assay. Plates were assayed for viability and proliferation for 10
days post-transfection. BrdU was added 24 hours prior to cell lysis
to allow sufficient time for DNA incorporation. After 24 hours,
cells were fixed, stained with anti-BrdU POD antibody (Roche)
and absorbance of BrdU was read at 440 nm.
HIV transfections
5610
6 Jurkat cells were transfected with 6 mg (unless otherwise
specified) GBV-C or control expression plasmid plus 1 mg (unless
otherwise indicated) HIV pNL4-3 plasmid in triplicate. Transfec-
tions were performed in an Amaxa Nucleofector II using
Nucleofection kit V. After transfection, cells were incubated in
RPMI supplemented with 10% fetal calf serum and 1% penicillin/
streptomycin/L-glutamine. Cell-free supernatants were collected
on the days indicated by centrifuging 650 mL of supernatant at 300
x g for 5 minutes removing the supernatant for analysis.
Supernatants were kept frozen at 280uC until p24 determination
in p24 ELISAs (Zeptometrix) according to the manufacturer’s
instructions. The p24 standard curve was derived by linear
regression using Excel software and used to calculate the p24
content of cell supernatants.
HIV receptor expression
5610
6 Jurkat cells were transfected with 1 mg GFP expression
sequence cloned into pCDNA3.1/Zeo+ (a marker for successful
transfection and protein expression) together with 6 mg NS3/4A/
4B or CAT expression plasmids and 500 pmole scrambled anti-
human CD4 siRNA [47,48]. As a control for measuring receptor
knock-down, cells were transfected with 1 mg GFP in pCDNA3.1/
Zeo+ with 6 mg CAT expression vector and 500 pmole anti-
human CD4 siRNA (for a final concentration of 5 mM in the
100 mL transfection buffer) [47,48]. Equal numbers of viable cells
were harvested on days 3, 4, and 5 and stained with anti-CD4 PE-
Cy7 and anti-CXCR4-PE (BD Pharmingen) and analyzed by flow
activated cell sorting (FACS) on a BD LSR II Flow Cytometer
[30]. Cells were analyzed first for GFP expression in comparison
with a no GFP control (CAT expression plasmid plus scrambled
anti-CD4 siRNA), then for CD4 and CXCR4 expression. At least
10,000 gated events were analyzed for each condition on each day.
Statistics
Two-way ANOVAs were used to compare the means of p24
values from supernatants collected across multiple days, with
Bonferroni’s post-test comparison to compare individual means.
Standard errors of means were calculated using Excel or
GraphPad Prism software.
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